Apr 05, 2021	Precipio Enters Into an At-The -Market (ATM) Financing Arrangement
Mar 30, 2021	Precipio Announces 95% Annual Growth YoY and 180% Quarterly Growth YoY
Mar 18, 2021	Precipio Announces Q4-2020 and year-end Shareholder Update Call
Mar 03, 2021	Mr. Ron Andrews joins Precipio’s Board of Directors
Mar 03, 2021	Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors
Jan 20, 2021	Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups
Dec 10, 2020	Precipio Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor
Nov 11, 2020	Precipio Announces Q3-2020 Shareholder Update Call
Oct 06, 2020	Precipio & ADS Biotec Launch Seven Beta sites for IV-Cell™
Sep 22, 2020	Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel
Sep 04, 2020	Precipio Announces a Shareholder Call to Discuss its COVID-19 Progress and Future Plans
Aug 20, 2020	Precipio & ADS Biotec Sign Global Distribution Agreement for IV-Cell™
Aug 07, 2020	Precipio Announces Q2-2020 Corporate Update Call For Shareholders
Aug 04, 2020	Precipio Launches Covid-19 Antibody Test in its CLIA laboratory
Jul 30, 2020	Precipio Announces Commercial Launch of Covid-19 Antibody Test
Jul 22, 2020	Precipio Announces Q2-2020 Unaudited Pathology Services Revenue Increased Approximately 50% over Q1’20
Jul 01, 2020	Precipio Regains Listing Compliance with NASDAQ Minimum Bid Requirement
Jun 09, 2020	Precipio Adds Another HemeScreen™ Customer
May 15, 2020	Q1-2020 Reported Revenues increase 77% over Q4-2019 to $1.2M
May 12, 2020	Precipio Announces Q1-2020 Corporate Update Call For Shareholders
Apr 06, 2020	Precipio Launches New HemeScreen™ Reagent Rental Program
Mar 20, 2020	Company Update During the COVID-19 Era
Mar 16, 2020	Precipio Completes the Transaction with Poplar Healthcare’s Oncometrix Hematopathology Division
Feb 26, 2020	Precipio achieves impressive initial results of Artificial Intelligence Decision-Support Tool
Feb 18, 2020	Precipio in advanced discussions with Poplar Healthcare towards a multi-faceted strategic partnership
Jan 28, 2020	Precipio Provides Clarification To Amendment No.1 to Form S-1 Filing
Jan 15, 2020	Precipio Provides Clarification To Recent S-1 Filing
Jan 13, 2020	Precipio announces shareholder update call to kick off 2020
Dec 17, 2019	Precipio Announces first IV-Cell™ Commercial Order from Northwell Health
Dec 04, 2019	Precipio Announces the Resignation of Samuel Riccitelli and the Introduction of Richard Sandberg to its Board of Directors
Nov 14, 2019	Precipio Wins $750,000 Pharma Project
Nov 14, 2019	Precipio Reports Superior Performance for IV-Cell™ in side-by-side analysis conducted by two major external laboratories
Nov 04, 2019	Precipio Announces Q3-2019 Corporate Update Call for Shareholders
Oct 09, 2019	Partners HealthCare and Precipio Enter into Pathology Services Agreement
Oct 02, 2019	Precipio announces shareholder update call on commercial progress
Sep 30, 2019	First Substantial Customer: Tennessee Oncology Internalizes Precipio's HemeScreen™
Sep 26, 2019	Clinical Validations for IV-Cell™ and HemeScreen™ Completed
Sep 05, 2019	Precipio and University of Pennsylvania Enter into Joint Collaboration Agreement for Pathology Diagnostics
Aug 13, 2019	Precipio Pathology Sales Metrics Demonstrate Continuous Improvement in Q2 2019
Aug 13, 2019	Precipio Announces Q2-2019 Corporate Update Call for Shareholders
Jul 22, 2019	Global Expansion Efforts Begin Yielding Results
Jun 25, 2019	Precipio and H3 Biomedicine Sign Second Development Agreement
Jun 17, 2019	Precipio CEO Provides Update Letter To Shareholders
Jun 04, 2019	Precipio Signs Exclusive Manufacturing Agreement for IV-Cell™
May 30, 2019	Precipio Pathology Sales Performance Metrics Demonstrate Substantial Improvement in Q1-2019
May 23, 2019	Precipio CEO Enrolls in Long Term Stock Purchase Plan
May 15, 2019	Precipio Regains Nasdaq Listing Compliance
May 06, 2019	Precipio Conducts IV-Cell™ Validation Trial with a Prominent Laboratory
May 03, 2019	Precipio Successfully Completes Nasdaq Hearing Process
May 01, 2019	Precipio Reminder of Corporate Update Shareholder Call
Apr 29, 2019	Precipio Signs First Major International Services Contract
Apr 26, 2019	Precipio Takes Final Step towards Regaining Nasdaq Compliance
Apr 24, 2019	Precipio Launches Global Expansion Strategy
Apr 18, 2019	Mr. Ori Karev Joins Precipio Executive Team As Chief Strategy Officer
Apr 15, 2019	Precipio Announces 2018 Year-End Corporate Update Call for Shareholders
Apr 09, 2019	Precipio Identifies Manufacturer for its IV-Cell Media
Apr 03, 2019	Precipio’s HemeScreen™ Adopted by Methodist Health
Mar 11, 2019	Precipio CEO Issues Shareholder Update Letter
Feb 18, 2019	Precipio Provides Corporate Update Shareholder Call
Feb 14, 2019	Precipio 2018 Revenues Increase 66% over 2017; Company Takes Substantial Cost-Cutting Measures Towards Profitability
Jan 15, 2019	Makati Medical Center in the Philippines Adopts Precipio’s ICE COLD-PCR Mutation Enrichment Technology for Liquid Biopsies
Jan 10, 2019	Precipio Announces First US Government Customer for ICE COLD-PCR™ Mutation Enrichment Technology
Jan 08, 2019	Precipio Files Patent for HemeScreen™, its Novel Molecular Assay
Dec 12, 2018	Precipio Reports Strong Mid-Quarter Growth
Dec 04, 2018	Precipio Announces $1.2 Million Securities Purchase Agreement With Participation from Members of Its Board of Directors, and other Investors
Nov 27, 2018	Precipio ICE COLD-PCR™ Technology Selected by the University of Cincinnati Medical Center for Liquid Biopsy Study
Nov 16, 2018	Proxy and Special Shareholder Meeting Letter From CEO
Nov 15, 2018	Precipio Announces Third Quarter 2018 Corporate Update Call for Shareholders
Nov 14, 2018	Webinar to Highlight Technology Underlying Precipio’s ICE COLD-PCR on November 20, 2018
Nov 01, 2018	Precipio and PerkinElmer Collaborate to Provide Solutions for Liquid Biopsy Testing Workflows
Oct 23, 2018	Precipio Expands ICE COLD-PCR™ Menu For Breast, Colon and Endometrial Cancers
Oct 18, 2018	Innovation Behind Precipio's ICE-COLD PCR™ Platform Spotlighted in Media
Oct 16, 2018	Precipio Announces Third Quarter 2018 Revenues Estimated at 2.4 Times Year-over-Year Q3-2017
Oct 03, 2018	Precipio Launches HemeScreen™, a Disruptive, Proprietary Molecular Test for Hematologic Cancers
Sep 27, 2018	Precipio Granted 180 Day NASDAQ Extension to Regain Compliance
Sep 20, 2018	Precipio Expands ICE-COLD PCR™ Lung Cancer Mutation Detection Offering
Aug 22, 2018	Precipio Reminds Investors of Conference Call with Management for Corporate Update and Second Quarter Results
Aug 17, 2018	Precipio Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Aug 09, 2018	Precipio Appoints New Board Member to Replace Departing Director
Jul 18, 2018	Precipio Announces 213% Year-over-Year Revenue Growth in Preliminary Q2-2018 Results
Jun 26, 2018	Precipio and Nucleai Partner to Develop Artificial Intelligence-Powered Hemepath Solution
Jun 19, 2018	Precipio Updates Commercial Pipeline for its ICE-COLD PCR™ Liquid Biopsy Technology
Jun 15, 2018	Precipio Inc. Announces Adjournment of Annual Meeting of Shareholders
Jun 14, 2018	Precipio Reminds Shareholders to Vote Before the Annual General Meeting on June 15, 2018
Jun 12, 2018	Precipio Reminds Shareholders to Vote Before the Annual General Meeting on June 15, 2018
Jun 06, 2018	Precipio Strengthens Patent Portfolio with Expanded Reagent Claims for its Liquid Biopsy Enabling DNA Mutation Enrichment Technology
May 24, 2018	Precipio Launches Liquid Biopsy DNA Enrichment Sales in Europe with First Order
May 22, 2018	Potential Sequential Revenue Run-Rate Growth of 30% over Q1, based on Preliminary April Results
May 17, 2018	Precipio Launches ICE COLD-PCR™ Liquid Biopsy Reagent for Pancreatic Cancer
May 14, 2018	Precipio Announces Preliminary Q1 2018 Year-over-Year Revenue Increase of 286%
Apr 26, 2018	Precipio Announces Participation Details for Upcoming Shareholder Conference Call
Apr 23, 2018	Precipio Completes a $3M Convertible Debt Facility
Apr 18, 2018	Precipio in Strategic Partnership Discussions for Proprietary Cytogenetics Media IV-Cell
Apr 17, 2018	Precipio Releases its 2017 10-K, Files a form S-1, and hosts Fourth Quarter and Full Year Update Call
Apr 11, 2018	Precipio Launches ICE COLD-PCR™ Research Access Program for Cancer Centers
Apr 03, 2018	Important JAMA Article Underscores Superiority of Precipio’s Liquid Biopsy Core Technology
Mar 28, 2018	Precipio Files Patent for Non-Invasive Cell Capture Device For Gynecological Cancer Detection
Mar 26, 2018	Precipio Enters India Liquid Biopsy Market with Adoption by Leading Laboratory
Mar 22, 2018	Precipio Restructures Capitalization Table
Mar 20, 2018	Precipio Integrates Cost Reducing and Fast Turnaround "High Resolution Melt" into Liquid Biopsy Platform
Mar 13, 2018	Precipio Settles Lawsuit with Crede Capital
Feb 22, 2018	Key Measure of Precipio’s Pathology Sales Growth 4X Prior Quarter
Feb 15, 2018	Precipio Launches Unique Lung Cancer Monitoring Test for Therapy Resistance
Feb 09, 2018	Precipio Announces Q4 2017 Revenue at 350% of Previous Quarter
Feb 06, 2018	Precipio Enters Japanese Liquid Biopsy Market with First Hospital Sale
Jan 22, 2018	Precipio Commences Validation Study of Proprietary IV-Cell Cytogenetics Media at University of Pennsylvania
Jan 16, 2018	Precipio Appoints New Sales VP to Manage Diagnostics Sales Expansion
Jan 10, 2018	Yale Study Demonstrates Four-Fold Superiority of Academic Level Diagnostic Accuracy

View All News Articles